CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 108 enrolled
Drug / intervention
1- Insulin glargine QHS +2 moredrug
Likely dose
1- Insulin glargine QHS 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00686712
NCT00686712Phase 4Completed
CompareCT.gov

The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy

Charles Drew University of Medicine and Science·interventional·Posted May 30, 2008·Updated May 22, 2017

In Brief

A Phase 4 clinical trial evaluating 1- Insulin glargine QHS, 2 - Insulin glargine QAM, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 108 participants across 1 site.

Detailed Summary

To compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral agents.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
CollaboratorsNational Center for Research Resources (NCRR)

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 30, 2008
Enrollment StartFeb 1, 2003
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 18.1 years ago

Interventions

1- Insulin glargine QHSdrug

Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings \<120 mg/dL)

2 - Insulin glargine QAMdrug

Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings \<120 mg/dL)

3 - NPH insulin QHSdrug

NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses \<120 mg/dL)